Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2017 (2017), Article ID 3615729, 10 pages
Research Article

Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus

1Virotherapy and Gene Therapy Group, ProCure Program, Translational Research Laboratory, Instituto Catalan de Oncología-IDIBELL, Barcelona, Spain
2Servei d'Anatomia Patològica, Hospital Universitari Arnau de Vilanova i Institut de Recerca Biomèdica de Lleida, Lleida, Spain
3Genomics and Cytomics Unit, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
4Cellular Biotechnology Laboratory, Institute of Health Carlos III (ISCIII), Majadahonda, Madrid, Spain

Correspondence should be addressed to R. Moreno; ten.aigolocnoci@oneromafar

Received 16 February 2017; Revised 19 April 2017; Accepted 4 May 2017; Published 11 July 2017

Academic Editor: Gerald A. Colvin

Copyright © 2017 R. Moreno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors. It is therefore of clinical relevance to improve OAdv bioavailability and tumor delivery. Among the variety of tumor-targeting strategies, the use of stem cells and specifically bone marrow-derived mesenchymal stem cells (BM-MSCs) is of particular interest due to their tumor tropism and immunomodulatory properties. Nonetheless, the invasive methods to obtain these cells, the low number of MSCs present in the bone marrow, and their restricted in vitro expansion represent major obstacles for their use in cancer treatments, pointing out the necessity to identify an alternative source of MSCs. Here, we have evaluated the use of menstrual blood-derived mesenchymal stem cells (MenSCs) as cell carriers for regional delivery of an OAdv in the tumor. Our results indicate that MenSCs can be isolated without invasive methods, they have an increased proliferation rate compared to BM-MSCs, and they can be efficiently infected with different serotype 5-based capsid-modified adenoviruses, leading to viral replication and release. In addition, our in vivo studies confirmed the tumor-homing properties of MenSCs after regional administration.